(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas

Diffuse low-grade and anaplastic gliomas (grades II and III, respectively) are infiltrative primary brain tumors that are considered malignant because of their invasiveness, resistance to therapy, and likelihood of transforming to higher grades. Median survival varies from 3 to 15 years as a proportion relentlessly progress, while others may remain stable for years (1).